Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00309946 · OUTCOME

Pharmacogenomics by Correlating Genetic Polymorphisms With Drug Activity and Toxicity

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery · Source last updated 2014-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Week 1 of course 1

What was measured

Focus on variants of genes in the pathway targeted by cediranib maleate, including kdr/flk-1 (the specific target of cediranib maleate) and the genes that encode Vascular endothelial growth factor A (VEGF-A) or HIF1α. If additional information relevant to other genes of interest in the pathway becomes available the samples will be utilized for such analysis as well.

Analysis population: This outcome was not measured/assessed for any of the study subjects.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor Therapy)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Focus on variants of genes in the pathway targeted by cediranib maleate, including kdr/flk-1 (the specific target of cediranib maleate) and the genes that encode Vascular endothelial growth factor A (VEGF-A) or HIF1α. If additional information relevant to other genes of interest in the pathway becomes available the samples will be utilized for such analysis as well.
groups
  1. description
    Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
    id
    OG000
    title
    Treatment (Enzyme Inhibitor Therapy)
population Description
This outcome was not measured/assessed for any of the study subjects.
reporting Status
POSTED
time Frame
Week 1 of course 1
title
Pharmacogenomics by Correlating Genetic Polymorphisms With Drug Activity and Toxicity
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice